High-Density Lipoprotein Subfractions - What the Clinicians Need to Know

Although the inverse relationship between plasma levels of high-density lipoprotein (HDL) and cardiovascular disease has been largely demonstrated, many observations have suggested that the assessment of HDL functionality might be more informative than a simple measurement of HDL-cholesterol plasma...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cardiology 2013-01, Vol.124 (2), p.116-125
Hauptverfasser: Pirillo, Angela, Norata, Giuseppe Danilo, Catapano, Alberico Luigi
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 125
container_issue 2
container_start_page 116
container_title Cardiology
container_volume 124
creator Pirillo, Angela
Norata, Giuseppe Danilo
Catapano, Alberico Luigi
description Although the inverse relationship between plasma levels of high-density lipoprotein (HDL) and cardiovascular disease has been largely demonstrated, many observations have suggested that the assessment of HDL functionality might be more informative than a simple measurement of HDL-cholesterol plasma levels. HDLs are a class of structurally and functionally heterogeneous particles; in atherosclerosis-related diseases, changes in HDL subfraction levels and functions are frequently observed. Circulating levels of large HDL particles are decreased in dyslipidaemic conditions, while levels of small dense HDL particles are increased in patients with coronary heart disease. Furthermore, specific genetic defects in proteins involved in HDL metabolism significantly impact the distribution of HDL subpopulations. Finally, many drugs used for dyslipidaemia induce changes in HDL subfractions strictly related to cardiovascular disease. Although several methods exist to evaluate HDL subclass levels, most of them are not easily applicable in clinical practice, due to the costs and high variability. However, the possibility to measure the levels of specific HDL subfractions in patients with atherosclerosis-related diseases might help to better define their cardiovascular risk.
doi_str_mv 10.1159/000346463
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1317847874</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1317847874</sourcerecordid><originalsourceid>FETCH-LOGICAL-c435t-e874ec5f9ba83e3eb4555619f39128ed817fc313eda4c4854c69ffb4cdbff9c93</originalsourceid><addsrcrecordid>eNpd0D1PwzAQBmALgWgpDOwIRWKBIRDHTmyPqHwUUcEAiDFynHNrSONiO0L99xi1dGA6-fT47vQidIyzS4wLcZVlGaElLckOGmKa41SwAu-iYezztCQ4H6AD7z_ikzKa76NBTmjOS0qHaDIxs3l6A503YZVMzdIunQ1guuSlr7WTKhjb-SRN3ucyJGEOybg1nVFGxu4TQJMEmzx29vsQ7WnZejja1BF6u7t9HU_S6fP9w_h6mipKipACZxRUoUUtOQECNS2KosRCE4FzDg3HTCuCCTSSKsoLqkqhdU1VU2stlCAjdL6eG-_86sGHamG8graVHdjeV5hgximLayI9-0c_bO-6eF1UucC8ZIJFdbFWylnvHehq6cxCulWFs-o33mobb7Snm4l9vYBmK__yjOBkDT6lm4Hbgs3_H7LIfDk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1329186797</pqid></control><display><type>article</type><title>High-Density Lipoprotein Subfractions - What the Clinicians Need to Know</title><source>MEDLINE</source><source>Karger Journals</source><creator>Pirillo, Angela ; Norata, Giuseppe Danilo ; Catapano, Alberico Luigi</creator><creatorcontrib>Pirillo, Angela ; Norata, Giuseppe Danilo ; Catapano, Alberico Luigi</creatorcontrib><description>Although the inverse relationship between plasma levels of high-density lipoprotein (HDL) and cardiovascular disease has been largely demonstrated, many observations have suggested that the assessment of HDL functionality might be more informative than a simple measurement of HDL-cholesterol plasma levels. HDLs are a class of structurally and functionally heterogeneous particles; in atherosclerosis-related diseases, changes in HDL subfraction levels and functions are frequently observed. Circulating levels of large HDL particles are decreased in dyslipidaemic conditions, while levels of small dense HDL particles are increased in patients with coronary heart disease. Furthermore, specific genetic defects in proteins involved in HDL metabolism significantly impact the distribution of HDL subpopulations. Finally, many drugs used for dyslipidaemia induce changes in HDL subfractions strictly related to cardiovascular disease. Although several methods exist to evaluate HDL subclass levels, most of them are not easily applicable in clinical practice, due to the costs and high variability. However, the possibility to measure the levels of specific HDL subfractions in patients with atherosclerosis-related diseases might help to better define their cardiovascular risk.</description><identifier>ISSN: 0008-6312</identifier><identifier>EISSN: 1421-9751</identifier><identifier>DOI: 10.1159/000346463</identifier><identifier>PMID: 23428644</identifier><language>eng</language><publisher>Basel, Switzerland: S. Karger AG</publisher><subject>Apolipoproteins - metabolism ; Cardiovascular disease ; Cardiovascular Diseases - blood ; Cardiovascular Diseases - drug therapy ; Cardiovascular Diseases - genetics ; Cholesterol Ester Transfer Proteins - antagonists &amp; inhibitors ; Enzyme Inhibitors - therapeutic use ; Fatty Acids, Omega-3 - administration &amp; dosage ; Fibric Acids - therapeutic use ; Humans ; Hypolipidemic Agents - therapeutic use ; Lipoproteins ; Lipoproteins, HDL - classification ; Lipoproteins, HDL - metabolism ; Lipoproteins, HDL - physiology ; Liver - metabolism ; Mutation - genetics ; Niacin - therapeutic use ; Turning Basic Research into Clinical Success</subject><ispartof>Cardiology, 2013-01, Vol.124 (2), p.116-125</ispartof><rights>2013 S. Karger AG, Basel</rights><rights>Copyright © 2013 S. Karger AG, Basel.</rights><rights>Copyright (c) 2013 S. Karger AG, Basel</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c435t-e874ec5f9ba83e3eb4555619f39128ed817fc313eda4c4854c69ffb4cdbff9c93</citedby><cites>FETCH-LOGICAL-c435t-e874ec5f9ba83e3eb4555619f39128ed817fc313eda4c4854c69ffb4cdbff9c93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,2429,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23428644$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pirillo, Angela</creatorcontrib><creatorcontrib>Norata, Giuseppe Danilo</creatorcontrib><creatorcontrib>Catapano, Alberico Luigi</creatorcontrib><title>High-Density Lipoprotein Subfractions - What the Clinicians Need to Know</title><title>Cardiology</title><addtitle>Cardiology</addtitle><description>Although the inverse relationship between plasma levels of high-density lipoprotein (HDL) and cardiovascular disease has been largely demonstrated, many observations have suggested that the assessment of HDL functionality might be more informative than a simple measurement of HDL-cholesterol plasma levels. HDLs are a class of structurally and functionally heterogeneous particles; in atherosclerosis-related diseases, changes in HDL subfraction levels and functions are frequently observed. Circulating levels of large HDL particles are decreased in dyslipidaemic conditions, while levels of small dense HDL particles are increased in patients with coronary heart disease. Furthermore, specific genetic defects in proteins involved in HDL metabolism significantly impact the distribution of HDL subpopulations. Finally, many drugs used for dyslipidaemia induce changes in HDL subfractions strictly related to cardiovascular disease. Although several methods exist to evaluate HDL subclass levels, most of them are not easily applicable in clinical practice, due to the costs and high variability. However, the possibility to measure the levels of specific HDL subfractions in patients with atherosclerosis-related diseases might help to better define their cardiovascular risk.</description><subject>Apolipoproteins - metabolism</subject><subject>Cardiovascular disease</subject><subject>Cardiovascular Diseases - blood</subject><subject>Cardiovascular Diseases - drug therapy</subject><subject>Cardiovascular Diseases - genetics</subject><subject>Cholesterol Ester Transfer Proteins - antagonists &amp; inhibitors</subject><subject>Enzyme Inhibitors - therapeutic use</subject><subject>Fatty Acids, Omega-3 - administration &amp; dosage</subject><subject>Fibric Acids - therapeutic use</subject><subject>Humans</subject><subject>Hypolipidemic Agents - therapeutic use</subject><subject>Lipoproteins</subject><subject>Lipoproteins, HDL - classification</subject><subject>Lipoproteins, HDL - metabolism</subject><subject>Lipoproteins, HDL - physiology</subject><subject>Liver - metabolism</subject><subject>Mutation - genetics</subject><subject>Niacin - therapeutic use</subject><subject>Turning Basic Research into Clinical Success</subject><issn>0008-6312</issn><issn>1421-9751</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpd0D1PwzAQBmALgWgpDOwIRWKBIRDHTmyPqHwUUcEAiDFynHNrSONiO0L99xi1dGA6-fT47vQidIyzS4wLcZVlGaElLckOGmKa41SwAu-iYezztCQ4H6AD7z_ikzKa76NBTmjOS0qHaDIxs3l6A503YZVMzdIunQ1guuSlr7WTKhjb-SRN3ucyJGEOybg1nVFGxu4TQJMEmzx29vsQ7WnZejja1BF6u7t9HU_S6fP9w_h6mipKipACZxRUoUUtOQECNS2KosRCE4FzDg3HTCuCCTSSKsoLqkqhdU1VU2stlCAjdL6eG-_86sGHamG8graVHdjeV5hgximLayI9-0c_bO-6eF1UucC8ZIJFdbFWylnvHehq6cxCulWFs-o33mobb7Snm4l9vYBmK__yjOBkDT6lm4Hbgs3_H7LIfDk</recordid><startdate>20130101</startdate><enddate>20130101</enddate><creator>Pirillo, Angela</creator><creator>Norata, Giuseppe Danilo</creator><creator>Catapano, Alberico Luigi</creator><general>S. Karger AG</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20130101</creationdate><title>High-Density Lipoprotein Subfractions - What the Clinicians Need to Know</title><author>Pirillo, Angela ; Norata, Giuseppe Danilo ; Catapano, Alberico Luigi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c435t-e874ec5f9ba83e3eb4555619f39128ed817fc313eda4c4854c69ffb4cdbff9c93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Apolipoproteins - metabolism</topic><topic>Cardiovascular disease</topic><topic>Cardiovascular Diseases - blood</topic><topic>Cardiovascular Diseases - drug therapy</topic><topic>Cardiovascular Diseases - genetics</topic><topic>Cholesterol Ester Transfer Proteins - antagonists &amp; inhibitors</topic><topic>Enzyme Inhibitors - therapeutic use</topic><topic>Fatty Acids, Omega-3 - administration &amp; dosage</topic><topic>Fibric Acids - therapeutic use</topic><topic>Humans</topic><topic>Hypolipidemic Agents - therapeutic use</topic><topic>Lipoproteins</topic><topic>Lipoproteins, HDL - classification</topic><topic>Lipoproteins, HDL - metabolism</topic><topic>Lipoproteins, HDL - physiology</topic><topic>Liver - metabolism</topic><topic>Mutation - genetics</topic><topic>Niacin - therapeutic use</topic><topic>Turning Basic Research into Clinical Success</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pirillo, Angela</creatorcontrib><creatorcontrib>Norata, Giuseppe Danilo</creatorcontrib><creatorcontrib>Catapano, Alberico Luigi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Proquest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pirillo, Angela</au><au>Norata, Giuseppe Danilo</au><au>Catapano, Alberico Luigi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>High-Density Lipoprotein Subfractions - What the Clinicians Need to Know</atitle><jtitle>Cardiology</jtitle><addtitle>Cardiology</addtitle><date>2013-01-01</date><risdate>2013</risdate><volume>124</volume><issue>2</issue><spage>116</spage><epage>125</epage><pages>116-125</pages><issn>0008-6312</issn><eissn>1421-9751</eissn><abstract>Although the inverse relationship between plasma levels of high-density lipoprotein (HDL) and cardiovascular disease has been largely demonstrated, many observations have suggested that the assessment of HDL functionality might be more informative than a simple measurement of HDL-cholesterol plasma levels. HDLs are a class of structurally and functionally heterogeneous particles; in atherosclerosis-related diseases, changes in HDL subfraction levels and functions are frequently observed. Circulating levels of large HDL particles are decreased in dyslipidaemic conditions, while levels of small dense HDL particles are increased in patients with coronary heart disease. Furthermore, specific genetic defects in proteins involved in HDL metabolism significantly impact the distribution of HDL subpopulations. Finally, many drugs used for dyslipidaemia induce changes in HDL subfractions strictly related to cardiovascular disease. Although several methods exist to evaluate HDL subclass levels, most of them are not easily applicable in clinical practice, due to the costs and high variability. However, the possibility to measure the levels of specific HDL subfractions in patients with atherosclerosis-related diseases might help to better define their cardiovascular risk.</abstract><cop>Basel, Switzerland</cop><pub>S. Karger AG</pub><pmid>23428644</pmid><doi>10.1159/000346463</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0008-6312
ispartof Cardiology, 2013-01, Vol.124 (2), p.116-125
issn 0008-6312
1421-9751
language eng
recordid cdi_proquest_miscellaneous_1317847874
source MEDLINE; Karger Journals
subjects Apolipoproteins - metabolism
Cardiovascular disease
Cardiovascular Diseases - blood
Cardiovascular Diseases - drug therapy
Cardiovascular Diseases - genetics
Cholesterol Ester Transfer Proteins - antagonists & inhibitors
Enzyme Inhibitors - therapeutic use
Fatty Acids, Omega-3 - administration & dosage
Fibric Acids - therapeutic use
Humans
Hypolipidemic Agents - therapeutic use
Lipoproteins
Lipoproteins, HDL - classification
Lipoproteins, HDL - metabolism
Lipoproteins, HDL - physiology
Liver - metabolism
Mutation - genetics
Niacin - therapeutic use
Turning Basic Research into Clinical Success
title High-Density Lipoprotein Subfractions - What the Clinicians Need to Know
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T13%3A42%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=High-Density%20Lipoprotein%20Subfractions%20-%20What%20the%20Clinicians%20Need%20to%20Know&rft.jtitle=Cardiology&rft.au=Pirillo,%20Angela&rft.date=2013-01-01&rft.volume=124&rft.issue=2&rft.spage=116&rft.epage=125&rft.pages=116-125&rft.issn=0008-6312&rft.eissn=1421-9751&rft_id=info:doi/10.1159/000346463&rft_dat=%3Cproquest_cross%3E1317847874%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1329186797&rft_id=info:pmid/23428644&rfr_iscdi=true